About Company
Body Organ Biomedical Corporation
The World Ophthalmic Tissue Repair Expert !
Body Organ Biomedical Corporation (BOBC) is dedicated to research and develop high-quality tissue regenerative solutions in ophthalmology. The ologen® Collagen Matrix, which is researched and developed by the company, has been the subject of more than 50 SCI/SCIE-indexed journals and indexed in 20 medical and professional textbooks worldwide. Besides ophthalmology, BOBC is also invested in surveying and developing regenerative solutions for dentistry, reconstructive surgery and general surgery.
Our Global Reach
BOBC, headquartered in Taipei, Taiwan, was founded in 2007 with an intensive R&D focus. It is partnered with its 100% wholly-owned subsidiary, Aeon Astron Europe B.V., which serves as a global production, marketing and delivery base as well as subsidiaries in the US, China and India for market penetration. The China subsidiary (Shanghai Aeon Astron) contains not only a business base but also a production plant that is estimated to be completed and inaugurated by 2021.
BOBC is constantly looking to increase its global partnerships to foster mutual benefit and maximize value creation.
Strategy
As the parent company, BOBC lays group-wide strategical plans by evaluating opportunities, ensuring IP protection, and being the research and development center of the group. The subsidiaries are each responsible of varying degrees of localized production, logistics and marketing.
Our Goal
At BOBC, we aim to serve patients, medical professionals and the society overall by developing and enabling access to innovative, safe and effective tissue-regeneration products.
With a strong foothold in ophthalmology, BOBC is also invested in surveying and developing quality regenerative solutions for dentistry, reconstructive surgery and general surgery to further address unmet medical needs in the world.
Aeon Astron Europe B.V.
Aeon Astron Europe B.V. (AAE) was incorporated in February 2008 in Leiden, the Netherlands as a wholly-owned subsidiary of Body Organ Biomedical Corporation (BOBC) with a mission to research, produce, market and deliver innovative regenerative products worldwide. Its current product line encompasses the ologen® Collagen Matrix, the Collagen Lens and the Biocornea, with the latter two currently under clinical investigation and development.
Global Marketing
AAE plans for the global promotion of its product line by maintaining top quality systems, obtaining product registrations (such as CE, Brazil ANVISA, Korea MFDS, USFDA-510K) and proactively collaborating with medical professionals, facilities and related parties both on a global and a local level to facilitate access.
Located in the logistically favorable Netherlands and powered with an experienced team, AAE drives product adoption and increases the ologen® brand awareness across the world. To date, ologen® Collagen Matrix is currently available in more than 40 nations and more than 80,000 operations have been carried out using ologen® Collagen Matrix. AAE is a supporting Glaucoma Industry Member of the World Glaucoma Association (WGA).
Resource Integration and Performance
Adept at integrating its academic, governmental and industry resources, AAE obtained a number of significant funding, subsidies and collaboration opportunities, including and not limited to the EU FP7 and Horizon 2020 as a testament to its global reputation and credit. AAE works with BOBC as a team to establish a platform for international collaboration and talent recruitment.
In the future this platform aims to include even more regenerative disciplines, including but not limited to dermatology, reconstructive surgery, orthopedics and general surgery provide a truly comprehensive range of product offerings.
Aeon Ajanta India Pvt. Ltd.
Aeon Ajanta India Ltd. (AAI) was incorporated in 2015 in New Delhi, India as a subsidiary of Aeon International B.V. to optimize the marketing and delivery of the group’s products in India, one of the key emerging markets in the strategy book of the group chairman, Mr. Lai. Mr. Lai has since laid out strategic objectives in promoting and affirming the first-line treatment qualifications of the ologen® products via evidence in safety and efficacy, the successful results of which are now reflected in worldwide business growth.
AAI, teemed with experienced local talents and leadership, works with the business group to complete high-barrier CDSCO registration and importation of medical devices, including the group’s own high-risk implants under the ologen® brand. By the end of 2019, the group’s ologen® Collagen Matrix has been adopted by medical practitioners coming from every state and used in more than 10,000 ophthalmic surgeries.
At the same time, AAI works with the group closely to conduct post-market surveillance and clinical studies to monitor product safety and efficacy on an ongoing basis. To date, there have been more than 20 journal articles reviewing clinical outcomes of the group’s product, from studies carried out at local medical universities, and led by leading ophthalmologists. The clinical adoption of the group’s product is expected to continue its growth with the amount of evidence accumulated, resulting in higher patient benefit.
Shanghai Body Organ Biomedical Corporation
Shanghai Body Organ Biomedical Corporation was established on May 15th, 2018.
Business scope: The research and development, manufacturing and sale of ophthalmic medical devices; medical device consultation services.
Address: Rm. 101, 1F, Building 4, No. 7001 Zhongchun Road, Minhang District, Shanghai (Minggu Technology Park).
- May 2018: Company was established in Shanghai, China.
- March 2019: Office established in Minhang District, Shanghai (Minggu Technology Park).
- April 2020: The Minggu Technology Park office officially launched; manufacturing plants and cleanrooms under construction.
Shanghai Aeon Astron Medical Corporation
Shanghai Aeon Astron Medical Corporation was established on July 30th, 2018.
Business scope: The research and development, manufacturing and sale of medical devices; medical device consultation services.
Address: Rm 108, 1F, Building 4, No. 7001 Zhongchun Road, Minhang District, Shanghai (Minggu Technology Park).